Ra Pharma is developing Cyclomimetics, a new drug class combining the properties and benefits of antibodies and small molecules.
Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs.It was founded in 2008 and headquartered in Cambridge, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 23, 2015 | Series B | $58.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Limulus Venture Partners | — | Series B |